Epithelial-mesenchymal transition, cancer stem cells and treatment resistance

Research output: Contribution to journalArticle

Bhuvanesh Dave, Vivek Mittal, Nicholas M. Tan, Jenny C. Chang

Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.

Original languageEnglish
Article number202
JournalBreast Cancer Research
Volume14
Issue number1
DOIs
StatePublished - Jan 19 2012

PMID: 22264257

PMCID: PMC3496111

Altmetrics

Cite this

Standard

Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. / Dave, Bhuvanesh; Mittal, Vivek; Tan, Nicholas M.; Chang, Jenny C.

In: Breast Cancer Research, Vol. 14, No. 1, 202, 19.01.2012.

Research output: Contribution to journalArticle

Harvard

Dave, B, Mittal, V, Tan, NM & Chang, JC 2012, 'Epithelial-mesenchymal transition, cancer stem cells and treatment resistance' Breast Cancer Research, vol. 14, no. 1, 202. https://doi.org/10.1186/bcr2938

APA

Dave, B., Mittal, V., Tan, N. M., & Chang, J. C. (2012). Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Research, 14(1), [202]. https://doi.org/10.1186/bcr2938

Vancouver

Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Research. 2012 Jan 19;14(1). 202. https://doi.org/10.1186/bcr2938

Author

Dave, Bhuvanesh ; Mittal, Vivek ; Tan, Nicholas M. ; Chang, Jenny C. / Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. In: Breast Cancer Research. 2012 ; Vol. 14, No. 1.

BibTeX

@article{78506669e6e64c8291d36e0f36e77830,
title = "Epithelial-mesenchymal transition, cancer stem cells and treatment resistance",
abstract = "Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.",
author = "Bhuvanesh Dave and Vivek Mittal and Tan, {Nicholas M.} and Chang, {Jenny C.}",
year = "2012",
month = "1",
day = "19",
doi = "10.1186/bcr2938",
language = "English",
volume = "14",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

RIS

TY - JOUR

T1 - Epithelial-mesenchymal transition, cancer stem cells and treatment resistance

AU - Dave, Bhuvanesh

AU - Mittal, Vivek

AU - Tan, Nicholas M.

AU - Chang, Jenny C.

PY - 2012/1/19

Y1 - 2012/1/19

N2 - Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.

AB - Breast cancer relapse, in a large number of patients, after initial response to standard of care therapy warrants development of novel therapies against recurrent and metastatic cancer. Cancer stem cells (CSCs), present in breast tumors while being intrinsically resistant to conventional therapy, have the ability to self renew and cause tumor recurrence. The residual tumors after therapy, with dramatic enrichment of the CSCs, have all the hallmarks of epithelial- mesenchymal transition (EMT). This review will focus on the link between EMT, CSCs and treatment resistance, since a better understanding of these interactions will allow us to effectively target the residual population after therapy.

UR - http://www.scopus.com/inward/record.url?scp=84856015098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856015098&partnerID=8YFLogxK

U2 - 10.1186/bcr2938

DO - 10.1186/bcr2938

M3 - Article

VL - 14

JO - Breast Cancer Research

T2 - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - 202

ER -

ID: 2562346